P/E ratio for Yield10 Bioscience (YTEN)
P/E ratio as of May 2024 (TTM): -1.04
According to Yield10 Bioscience's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.03597. At the end of 2022 the company had a P/E ratio of -0.6051.
P/E ratio history for Yield10 Bioscience from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.6051 | -71.22% |
| 2021 | -2.10 | 70.97% |
| 2020 | -1.23 | 495.9% |
| 2019 | -0.2064 | -76.88% |
| 2018 | -0.8925 | 65.38% |
| 2017 | -0.5396 | -56.68% |
| 2016 | -1.25 | -22.36% |
| 2015 | -1.60 | 145.19% |
| 2014 | -0.6543 | -53.79% |
| 2013 | -1.42 | -109.57% |
| 2012 | 14.8 | -506.59% |
| 2011 | -3.64 | -56.63% |
| 2010 | -8.39 | 23.05% |
| 2009 | -6.82 | -15.81% |
| 2008 | -8.10 | -57.11% |
| 2007 | -18.9 | 221.57% |
| 2006 | -5.87 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | 221.76% | Bahamas |
 NRC Health
NRC | 26.5 | -2,660.02% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.